培美曲塞单药治疗复治晚期肺腺癌27例疗效分析

目的 探讨培美曲塞单药治疗复治晚期肺腺癌的疗效及毒副反应.方法 27例复治晚期肺腺癌,给予培美曲塞500 mg/m2,静脉滴注,d1,每3周重复;并口服地塞米松、叶酸和肌内注射维生素B12以减轻毒副反应.每2个周期后进行疗效评价.结果 27例患者均可评价疗效,疗效评价为CR 0例,PR 3例,SD 10例,PD 14例...

The Clinical Investigation of Efficacy by Pemetrexed for 27 Patients with Pulmonary Adenocarcinoma After Failure of First-Line Treatment

Objective To evaluate the efficacy and toxicities by pemetrexed alone in the treatment of pulmonary adenocarcinoma after failure of first-line treatment.Methods The 27 patients were enrolled.All of these patients had been confirmed with pathology or cytology and received pemetrexed 500 mg/m2 on day 1,by intravenous infusion,with every 21 days.Dexamethasone,folic acid and vitamin B12 they were applied to relieve the drug toxicity.All the patients who received 2 or more cycles could be evaluated.Results There was no case with complete response.Three cases had partial response,10 cases stable disease and 14 cases had progressive disease.The response rate was 11.1%(3/27).The disease control rate was 48.1%(13/27).The median progression free survival was 2.8 months.The median overall survival was 10.6 months.The most common toxicities were grade Ⅰ-Ⅱ myelosuppression and gastrointestinal reaction.Conclusion Pemetrexed is effective and feasible for advanced recurrent pulmonary adenocarcinoma.